StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)

Close on Nov 16, 2026Market cap $1.56BP/E –Yield –

Recursion Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Recursion Pharmaceuticals's total assets was $1.21B at Jun 30, 2026. For fiscal 2025 it was $1.47B, up 1.8% from the year before. The highest annual figure on record is $1.47B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.47B+1.8%
FY2024Dec 31, 2024$1.45B+121.6%
FY2023Dec 31, 2023$653.70M-6.8%
FY2022Dec 31, 2022$701.29M+14.9%
FY2021Dec 31, 2021$610.35M+104.4%
FY2020Dec 31, 2020$298.59M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.21B-6.9%
Q1 FY2026Mar 31, 2026$1.34B+2.6%
Q4 FY2025Dec 31, 2025$1.47B+1.8%
Q3 FY2025Sep 30, 2025$1.40B+92.6%
Q2 FY2025Jun 30, 2025$1.30B+67.9%
Q1 FY2025Mar 31, 2025$1.31B+134.0%
Q4 FY2024Dec 31, 2024$1.45B+121.6%
Q3 FY2024Sep 30, 2024$726.50M+15.2%
Q2 FY2024Jun 30, 2024$775.86M+16.4%
Q1 FY2024Mar 31, 2024$557.85M-11.1%
Q4 FY2023Dec 31, 2023$653.70M-6.8%
Q3 FY2023Sep 30, 2023$630.83M+3.2%
Q2 FY2023Jun 30, 2023$666.70M-0.9%
Q1 FY2023Mar 31, 2023$627.37M-14.6%
Q4 FY2022Dec 31, 2022$701.29M+14.9%
Q3 FY2022Sep 30, 2022$611.53M-7.1%
Q2 FY2022Jun 30, 2022$672.52M-3.7%
Q1 FY2022Mar 31, 2022$734.32M+170.0%
Q4 FY2021Dec 31, 2021$610.35M+104.4%
Q3 FY2021Sep 30, 2021$658.61M–
Q2 FY2021Jun 30, 2021$698.59M–
Q1 FY2021Mar 31, 2021$271.94M–
Q4 FY2020Dec 31, 2020$298.59M–

More Recursion Pharmaceuticals figures

See a number that looks wrong?